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ABSTRACT
Erythema multiforme (EM) is an acute, self-limiting, often recurrent disease, with or without mucosal 
involvement, which occurs in an IV type hypersensitivity reaction provoked by infectious, medication, 
physical, chemical, etc. agents. In erythema multiforme related to the human herpes virus type 1 (HHV-1) 
infection, the skin and mucosal manifestations are a result from a cell-mediated immune response, directed 
against HSV-DNA polymerase-positive antigen cells (keratinocytes). 
We present a clinical case of a 33-year-old female patient with recurrent labial herpes followed by a clinical 
appearance of EM. About a week after the resolution the herpes recurrence, burning and itchy erythematous 
target lesions and blisters occurred involving upper and lower limbs, then spread to the face, neck, neckline, 
typical for EM. In some of the target lesions, a central blister appeared, surrounded by vesicles - herpes iris 
of EM type. Serology tests established high positive antibodies to HSV-1 of IgG type (154 UI/mL). Based 
on the characteristic clinical findings we diagnosed herpes iris erythema multiforme, related to HHV1 
infection. The presented case is an interesting manifestation of the morphological type of EM, described by 
Thomas Bateman in 1817, “herpes iris”, preceded by a relapse of the herpes infection.
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INTRODUCTION
Erythema multiforme (EM) is an acute, self-
limiting but recurrent disease with skin and muco-
sal involvement due to an IV type hypersensitivity 
reaction induced by infectious, medication, physi-
cal and chemical agents (1). EM was originally de-
scribed in 1817 by Thomas Bateman in his derma-
tological atlas “Delineations of Cutaneous Diseases” 
as a concentric “target” or “iris”-like lesion (2). Lat-
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blister appeared, surrounded by the vesicles - herpes 
iris of erythema multiforme type (Fig. 4, Fig. 5). 
Routine laboratory investigations did not dem-
onstrate any abnormalities. Virological tests assessed 
er in 1886, Ferdinand von Hebra distinguished EM 
as an acute, self-limiting but often relapsing disease, 
which affects symmetrically the limbs and is mani-
fested by the characteristic target lesions (3). In 1922, 
American physicians Stevens and Johnson described 
two clinical cases in 7- and 8-year-old boys who de-
veloped generalized eruption with persistent fever, 
sore buccal mucosa and purulent conjunctivitis. This 
state was subsequently called Stevens-Johnson syn-
drome (SJS) (3,4). In 1950, Bernard Thomas, in his 
article “So-Called Stevens-Johnson Syndrome”, ana-
lyzed the clinical presentation of EM and proposed 
classification of EM into two types, according to the 
severity of the skin lesions: EM minor (von Hebra) 
and EM major, known by many researchers as SJS 
(5). In one of the most cited articles, published in the 
British Journal of Dermatology in 1956, Alan Lyell 
described four clinical cases (3 women and 1 man) 
with a severe bullous reaction and epidermal necrol-
ysis, called toxic epidermal necrolysis (TEN) or Ly-
ell syndrome, preceded by a medication treatment 
(6). In 1993, an international group of dermatologists 
proposed a new classification of the EM depending 
on the etiological agent (drug or infection) and the 
prognosis. The new classification distinguished EM 
minor, EM major, and SJS/TEN. EM minor and ma-
jor are mostly recurrent, post-infectious (herpes sim-
plex, mycoplasma) diseases with relatively low-grade 
illness and low mortality risk. SJS and TEN are drug-
induced reactions with severe manifestation and 
worse prognosis (7).
CASE DESCRIPTION
We present a 33-year-old female patient, suf-
fering from a labial herpes with frequent recurrence 
of 5 to 6 times per year. One week after the current 
relapse of the labial herpes she was admitted in the 
clinic because of burning and itchy erythemic tar-
get lesions and blisters located on the upper and low-
er limbs and then spreading to the skin of the face, 
neck and neckline (Fig. 1 and Fig. 2). The lesions were 
found to be typical for EM. On the upper lip of the 
patient there was still a sign of the resolved herpes le-
sion - a brown oval crust of about 0.5 cm (Fig. 3). Ve-
siculobullous exanthema was accompanied by fever 
up to 38˚C, conjunctival redness, muscle pain and a 
general malaise. In some of the target lesions, central 
Fig. 1. Blisters
Fig. 2. Target lesions and blisters
Fig. 3. Resolved herpes lesion on the upper lip
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highly positive antibodies to herpes simplex virus 
type 1 (HSV-1) of IgG type (titer 154 IU/mL), nega-
tive HSV-1 IgM antibodies, negative herpes simplex 
virus type 2 (HSV-2) IgM and IgG antibodies, as well 
as negative varicella zoster virus (VZV) IgM antibod-
ies, HIV P24 antigen and HIV 1/2 serology. Based on 
the recent human herpes virus type 1 (HHV-1) labi-
al infection, classical target lesions and conjunctival 
and oral mucosal involvement the diagnosis of her-
pes iris erythema multiforme was established.
The patient was treated with acyclovir 400 mg 
orally five times per day, gentamicin 160 mg intrave-
nously for five days,  methylprednisolone 40 mg  intra-
venously for three days, and methylprednisolone 20 
mg  intravenously for four days. After the treatment, 
skin and oral lesions were controlled. The swelling 
and the redness of the face healed in three days. The 
patient’s rash and erosions were improving. On the 
day of discharge acyclovir was prescribed prophylac-
tically for 30 days, 400 mg two times per day. It is 
considered that in patients with recurrent EM, anti-
viral therapy has shown to be an effective prevention 
of both recurrent herpes and EM. The best response 
to therapy occurs in patients with a clear correlation 
between herpes simplex infection and EM. The dos-
age of 800 mg/24h oral acyclovir has been shown to 
be effective in preventing recurrent herpes simplex. 
Antiviral therapy has shown to be an effective pro-
phylaxis and can last from several weeks to several 
months. One month later, the patient returned with 
new lesions characterized by diffuse papules, single 
vesicle lessions and target lessions, involving her back 
of arms and forearms. Of note was that no history of 
febrile episode, conjunctival injection, general mal-
aise or oral lessions were present this time. The pa-
tient was treated with a 7-day course of acyclovir (400 
mg/5 times per day), methylprednisolone 4 mg tabl. 
three time per day for five days. Within 7 days, all 
the lesions healed. Because of the recurring episodes, 
acyclovir was given prophylactically for one more 
month, 400 mg/2 times per day. In addition, no oral 
or skin lesions developed 6 months after treatment.
DISCUSSION
In that case, EM is related to the recurrent HHV-
1 infection. This association has been confirmed in a 
scientific literature and HHV-DNA has been discov-
ered in skin biopsies by the polymerase chain reac-
tion (PCR) technique in 60% of the 63 studied pa-
tients with EM and recurrent herpes (8). The mani-
festation of labial herpes in our patient preceded the 
EM appearance by a week. A similar sequence is reg-
Fig. 4. Herpes iris EM type 
Fig. 5. Central blister surrounded by the vesicles
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istered in other studies, supporting the hypothesis 
of a relationship between HHV-1 and EM. The skin 
and mucosal manifestations of HHV1 EM are asso-
ciated with cell-mediated immune reaction to HSV 
DNA and HSV antigens in the keratinocytes (1). The 
cytotoxic CD8-positive T-cell lymphocytes found in 
the epidermis induce apoptosis and necrosis in the 
surrounding keratinocytes (9). The suggested mech-
anism led to morphological expression, described by 
Thomas Bateman as herpes iris skin lesions, which 
are also demonstrated in the presented case. Acyclo-
vir is an antiviral drug that penetrates HSV-infect-
ed cells. To become effective, acyclovir must first be 
converted to acyclovir monophosphate by an en-
zyme that is only found in viruses, called thymidine 
kinase. It is then converted to its active triphosphate 
form by human enzymes found inside the cells. Acy-
clovir triphosphate binds to and inhibits the elonga-
tion of viral DNA (10). Long-term suppressive ther-
apy with acyclovir has been shown to decrease re-
currence of HSV. Suppression of HSV can prevent 
HSV-associated EM (11). In the case we report, EM 
relapsed one month after discontinuation of acyclo-
vir therapy. In our patient the last relapse of EM was 
not preceded by clinically manifested labial herpes. 
Probably in part of recurrences of herpes simplex, 
there was no full-blown clinical picture of grouped 
vesicular rash (12). For this reason, we assume that 
upon discontinuation of prophylaxis with acyclovir, 
subclinical activation of the virus has occurred, with 
subsequent mild recurrence of EM, without lesion of 
the conjunctiva, and without damaging the patient’s 
general condition. Recurrence is seen in approxi-
mately 20–25% of EM cases. The recurrence rate may 
vary between 2 and 24 per year, lasting 10-20 days 
each. Typically, herpes-associated EM appears on av-
erage over 10 years and lasts between 2 and 36 years 
in  different patients (13). Herpes-associated EM can 
be controlled by continuous (up to 26 weeks) sup-
pressive treatment with oral acyclovir (200-800 mg). 
When acyclovir inefficiency is detected, valacyclo-
vir (500 mg) can be used 2 times per day. Valacyclo-
vir might provide better therapeutic results and low-
er the risk of selecting acyclovir-resistant viral strains 
in patients with recurrent EM (13).
CONCLUSION
In conclusion, our clinical case illustrates and 
confirms the relationship between the HHV infec-
tion and EM, demonstrated with characteristic “tar-
get-like” and “herpes iris” skin changes.
REFERENCES
1. Sokumbi O, Wetter DA. Clinical features, di-
agnosis, and treatment of erythema multi-
forme: a review for the practicing dermatolo-
gist. Int J Dermatol. 2012;51(8):889–902. doi: 
10.1111/j.1365-4632.2011.05348.x.
2. Levell NJ. Thomas Bateman MD FLS 1778-
1821. Br J Dermatol. 2000;143(1):9–15. doi: 
10.1046/j.1365-2133.2000.03582.x.
3. 3Wolf R, Lipozencic J. Shape and configu-
ration of skin lesions: targetoid lesions. Clin 
Dermatol. 2011;29(5):504–8.  doi: 10.1016/j.
clindermatol.2010.09.020.
4. Stevens AM, Johnson FC. A new eruptive fe-
ver associated with stomatitis and ophthal-
mia. Am J Dis Child. 1922;24(6):526. doi:10.1001/
archpedi.1922.04120120077005.
5. Thomas BA. So-called Stevens—Johnson Syn-
drome. Br Med J. 1950;1(4667):1393.  doi: 10.1136/
bmj.1.4667.1393.
6. Lyell A. Toxic epidermal necrolysis: an eruption 
resembling scalding of the skin. Br J Dermatol. 
1956;68(11):355–61. doi: 10.1111/j.1365-2133.1956.
tb12766.x.
7. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Na-
ldi L, Roujeau JC. Clinical classification of cases of 
toxic epidermal necrolysis, Stevens-Johnson syn-
drome, and erythema multiforme. Arch Dermatol. 
1993;129(1):92–6. 
8. Ng PPL, Sun YJ, Tan HH, Tan SH. Detection of 
herpes simplex virus genomic DNA in various sub-
sets of erythema multiforme by polymerase chain 
reaction. Dermatology. 2003;207(4):349–53. doi: 
10.1159/000074112.
9. Huff JC. Erythema multiforme and latent her-
pes simplex infection. Semin Dermatol. 
1992;11(3):207–10. 
10. King DH. History, pharmacokinetics, and pharma-
cology of acyclovir. J Am Acad Dermatol. 1988;18(1 
Pt 2):176–9. doi: 10.1016/s0190-9622(88)70022-5. 
11. Shelley WB. Herpes simplex virus as a 
cause of erythema multiforme. JAMA J Am 
Scripta Scientifica Medica, 2019;51(3):27-31
Medical University of Varna 31
Stoyan Pavlov, Zhanina Barzakova
Med Assoc. 1967;201(3):153–6. doi:10.1001/
jama.1967.03130030023005.
12. Daikoku T, Tannai H, Honda M, Onoe T, Matsuo 
K, Onoye Y, et al. Subclinical generation of acyclo-
vir-resistant herpes simplex virus with mutation  of 
homopolymeric guanosine strings during acyclo-
vir therapy. J Dermatol Sci. 2016;82(3):160–5. doi: 
10.1016/j.jdermsci.2016.02.006.
13. Osterne RLV, Matos Brito RG de, Pacheco IA, Alves 
APNN, Sousa FB. Management of erythema multi-
forme associated with recurrent herpes infection: a 
case report. J Can Dent Assoc. 2009;75(8):597–601.
